Galderma has received a Complete Response Letter (CRL) from the US FDA for relabotulinumtoxinA, the company's next-generation botulinum toxin candidate, halting — at least temporarily — its push to bring a fourth-to-market neuromodulator to US aesthetic practices.

The CRL, reported by The Dermatology Digest, means the FDA has declined to approve the Biologics License Application in its current form. For Galderma, the letter interrupts the US leg of a launch sequence the company has built around relabotulinumtoxinA as a successor and complement to its established portfolio, which includes the Restylane filler range and the widely used dysport-type neuromodulator platform.

What does a Complete Response Letter actually change?

A CRL is not a formal rejection. It signals that the FDA has identified deficiencies — which can range from manufacturing site inspection issues to clinical data requests or labeling negotiations — that must be resolved before approval can be granted. The agency does not publish the letter's contents; disclosure sits with the applicant.

For Galderma, the practical consequences are procedural: the approval clock stops, the company must prepare a response addressing the FDA's cited deficiencies, and any US launch timing shifts to the right. Neither the specific deficiencies nor a revised timeline appeared in the initial reporting, so the duration of the delay remains the open variable for anyone modeling the US neuromodulator market.

Why the stakes are high in the toxin category

The US aesthetic neuromodulator market is dominated by Allergan's onabotulinumtoxinA (Botox Cosmetic), with Ipsen/Ipsen-partnered and Merz products competing for share. A new entrant from Galderma — a company with one of the largest aesthetics field forces in dermatology and plastic surgery — would have added pricing and formulary pressure across medspas, dermatology clinics and plastic surgery practices.

For practitioners, a delayed approval means treatment menus stay unchanged: existing toxin options remain the only FDA-cleared injectables for glabellar and forehead dynamics, and procurement teams at multi-site aesthetic groups can defer any supplier diversification planning.

For competing suppliers — AbbVie, Ipsen, Merz, and Evolus among them — the CRL buys additional quarters of market stability and removes a near-term share-erosion scenario from their forecasts.

What comes next for Galderma

The standard path forward is a response filing that addresses each deficiency, followed by another FDA review cycle. Depending on the nature of the issues, that process can take months to more than a year. If the deficiencies are limited to facility inspections or labeling, resolution can be comparatively fast; if the agency wants additional clinical data, the timeline extends considerably.

Galderma has not yet publicly detailed the contents of the CRL or its response plan, according to the initial report. The company's disclosure — typically via a press release or investor communication — is the next data point to watch, along with any revised US filing or resubmission timeline it provides.